The coronavirus pandemic is really paying off for Pfizer, which expects to rake in about $US15 billion ($A19.65 billion) from its coronavirus vaccine this year – about a quarter of its entire projected 2021 revenue.
The drug, developed with German partner BioNTech, has a profit margin of more than 20 per cent, the company said.